All News

2018

July

Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Read More

June

Media Release / Jun 03, 2018

Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Read More

May

Media Release / May 17, 2018

Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

Read More
Media Release / May 16, 2018

At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth

Read More

March

Media Release / Mar 20, 2018

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

Read More
Media Release / Mar 01, 2018

Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis

Read More

January

Media Release / Jan 03, 2018

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Read More
2017

December

Media Release / Dec 06, 2017

Kisqali® first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer

Read More

November

Media Release / Nov 14, 2017

Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy

Read More
Media Release / Nov 08, 2017

Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More